儿童患者自主呼吸恢复后常规使用新斯的明与神经肌肉监测指导使用新斯的明的比较:一项平行随机对照研究
本研究为平行随机对照非劣效性试验,纳入120例3月龄至12岁行腹股沟疝修补术的患儿,比较自主呼吸恢复后常规给予新斯的明0.02 mg/kg与神经肌肉监测指导给药对拔管后残余神经肌肉阻滞发生率的影响。结果显示两组残余阻滞发生率无显著差异(45/60 vs 44/60,RR 1.02,95%CI 0.83至1.26,p=0.84),但实验组手术结束至离开手术室时间更早(13.6±5.2 vs 15.7±5.6分钟,MD -2.10分钟,95%CI -3.70至-0.50,p=0.04),探索性分析中实验组TOF比值<0.3的风险比为31.12(95%CI 1.89至512.61)。
要点
- 拔管后残余神经肌肉阻滞发生率两组无显著差异(45/60 vs 44/60,RR 1.02,95%CI 0.83至1.26,p=0.84)。
- 实验组手术结束至离开手术室时间早于对照组(13.6±5.2 vs 15.7±5.6分钟,MD -2.10分钟,95%CI -3.70至-0.50,p=0.04)。
- 探索性分析中实验组TOF比值<0.3的风险比为31.12(95%CI 1.89至512.61),对照组为0/60。
核心结论
- 在儿童小手术后,自主呼吸恢复可作为神经肌肉监测的替代指标来指导新斯的明使用,但需注意残余神经肌肉阻滞。
研究设计与样本
- 平行、随机、对照非劣效性研究,纳入120例3月龄至12岁行腹股沟疝修补术的患儿,实验组和对照组各60例。
主要发现
- 拔管后残余神经肌肉阻滞发生率两组无显著差异(45/60 vs 44/60,RR 1.02,95%CI 0.83至1.26,p=0.84)。
- 两组均未发生新斯的明诱导的肌肉麻痹,不良事件发生情况相似。
- 实验组手术结束至离开手术室时间早于对照组(13.6±5.2 vs 15.7±5.6分钟,MD -2.10分钟,95%CI -3.70至-0.50,p=0.04)。
- 探索性分析中实验组TOF比值<0.3的风险比为31.12(95%CI 1.89至512.61),对照组为0/60(12/60 vs 0/60,p=0.00)。
临床怎么用
- 作者认为,儿童小手术后可以自主呼吸恢复作为神经肌肉监测的替代指标来指导新斯的明使用,但需注意残余神经肌肉阻滞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neostigmine used to reverse the muscle relaxants should be guided by neuromuscular monitoring, as the degree of spontaneous pre-reversal recovery is the key to success to reverse the neuromuscular block. But neuromuscular monitoring is not always available for some patients during anesthesia and, in consequence, we need to use other clinical judgment to guide the use of neostigmine to reverse the neuromuscular block. In this trial, we aimed to evaluate the incidence of residual neuromuscular blockade (rNMB) in pediatric patients with routine use of neostigmine after recovery of spontaneous breathing compared with the patients with the use of neostigmine guided by neuromuscular monitoring. METHODS: A parallel, randomized, controlled noninferiority study was conducted. We enrolled aged 3 months to 12 years old patients who underwent inguinal hernia repair under general anesthesia. The enrolled patients were randomly divided into experimental and control groups. After surgery, children in the experimental group were given 0.02 mg/kg neostigmine after recovery of spontaneous breathing. Children in the control group were given 0.02 mg/kg neostigmine when the train-of-four (TOF) ratio was between 0.4 and 0.9. However, no neostigmine was administered if the TOF ratio was higher than 0.9. The primary outcome was the incidence of rNMB after extubation (TOF ratio < 0.9). Secondary outcomes included the incidence of neostigmine-induced muscle paralysis, end of surgery - extubation interval, end of surgery - exit OR interval, the length of stay in the PACU, the incidence of hypoxia in the PACU, the number of children who required assisted ventilation during the PACU stay, and neostigmine-related adverse events. RESULTS: A total of 120 children were included in this study, with 60 in the experimental group and 60 in the control group. There was no significant difference in the incidence of rNMB after extubation between the groups (45/60 vs 44/60, RR 1.02 [95% CI, 0.83 to 1.26], p = 0.84). There was no neostigmine-induced muscle paralysis in either group. Adverse events were similar occurred in both groups. However, time from end of the surgery to leaving the operating room was earlier in the experimental group than in the control group (13.6 ± 5.2 vs 15.7 ± 5.6 min, MD -2.10 min [95% CI, -3.70 to -0.50], p = 0.04). The risk ratio of the incidence of TOF ratio < 0.3 for the experimental group was 31.12 (95%CI, 1.89 to 512.61) compared with the control group (12/60 vs 0/60, p = 0.00) in exploratory analysis. CONCLUSIONS: Recovery of spontaneous breathing could be used as a substitute of neuromuscular monitoring to guide neostigmine use in pediatric patients following minor surgeries. However, care should be taken for the residual neuromuscular block. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-IOR-17012890. Registered on 5 October 2017.
引用
- Yang L, Hu N, Chang H, et al. Routine administration of neostigmine after recovery of spontaneous breathing versus neuromuscular monitor-guided administration of neostigmine in pediatric patients: a parallel, randomized, controlled study. Trials. 2023. PMID: 36611181. doi:10.1186/s13063-023-07066-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。